Jaguar Health Inc. $(JAGX)$ has announced an extension of the maturity date for its convertible promissory notes from the recent bridge financing. The new maturity date is set for January 30, 2026, extending from the previous date of June 30, 2025. This change affects approximately $2.57 million in aggregate principal amount of the notes, which were part of a $3.448 million bridge financing deal that closed on March 31, 2025. Prior to this extension, five investors converted $0.866 million of the original financing into equity. CEO Lisa Conte expressed satisfaction with the agreement, highlighting the investors' commitment to supporting Jaguar's development programs for its plant-based medicine, crofelemer.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。